Inhibrx Biosciences, Inc.

# Signal Note: Perceptive Advisors Initiates $114.8M Position in Inhibrx Perceptive's entry suggests conviction in Inhibrx's clinical-stage pipeline, likely centered on INBRX-109 (DR5 agonist) for solid tumors and INBRX-105 (CTLA-4/OX40 bispecific) in oncology, both in early-stage development. The ~$115M position (meaningful for a stage investor) implies confidence in near-term clinical readouts or partnership catalysts that could de-risk the platform. Near-term value drivers include Phase 1b/2 data on lead assets and potential licensing deals that validate the bispecific antibody technology.